B · Normal
[Gilead: The one-year persistence of lenacapavir administered once every six months in HIV prevention is nearly twice that of daily oral F/TDF] On November 7, Gilead disclosed data showing that the one-year persistence of lenacapavir administered once every six months in HIV prevention is nearly twice that of daily oral F/TDF. Lenacapavir achieved 85.6% one-year PrEP persistence at week 52; during the 52-week study period, no HIV infection occurred in the lenacapavir group, and 1 infection was reported in the daily oral F/TDF group; serious adverse events were uncommon and unrelated to treatment, and there were no treatment discontinuations due to adverse events in the lenacapavir group.
Comments